NAD + homeostasis in human health and disease
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Abstract Depletion of nicotinamide adenine dinucleotide (NAD + ), a central redox cofactor and the substrate of key metabolic enzymes, is the causative factor of a number of inherited and acquired diseases in humans. Primary deficiencies of NAD + homeostasis are the result of impaired biosynthesis, while secondary deficiencies can arise due to other factors affecting NAD + homeostasis, such as increased NAD + consumption or dietary deficiency of its vitamin B3 precursors. NAD + depletion can manifest in a wide variety of pathological phenotypes, ranging from rare inherited defects, characterized by congenital malformations, retinal degeneration, and/or encephalopathy, to more common multifactorial, often age‐related, diseases. Here, we discuss NAD + biochemistry and metabolism and provide an overview of the etiology and pathological consequences of alterations of the NAD + metabolism in humans. Finally, we discuss the state of the art of the potential therapeutic implications of NAD + repletion for boosting health as well as treating rare and common diseases, and the possibilities to achieve this by means of the different NAD + ‐enhancing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008 · cited 3×
“Sirtuins are a family of NAD+-dependent protein deacetylases that, in mammals, consists of seven members (SIRT1 to SIRT7) with different subcellular locations (Michishita et al, 2005; Houtkooper et al, 2012).”
BackgroundMethodSelf-citationBrown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · cited 1×
“Through this mechanism, NA and its derivative acipimox act as lipid- and cholesterollowering agents in humans (Sirtori et al, 1981; Taskinen & Nikkila, 1988; Berge & Canner, 1991; Brown et al, 2001; Westphal et al, 2006).”
BackgroundWilliamson, D., Lund, P., & Krebs, H. (1967) · Biochemical Journal · doi:10.1042/bj1030514 · Cited by 1,871 · cited 1×
“Indeed, the nuclear and cytoplasmic NAD+:NADH ratio is 700:1, whereas that in mitochondria is much lower (8:1) (Williamson et al, 1967).”
BackgroundCantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · cited 2×
“Until very recently, six molecules were considered to act as extracellular NAD+ precursors including tryptophan, NA, NAM, nicotinic acid riboside (NaR), NMN, and NR (Tempel et al, 2007; Canto et al, 2015; Rajman et al, 2018).”
BackgroundYing, W. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1672 · Cited by 1,494 · cited 4×
“For more information about the implications of the NAD+:NADH balance, diseases affecting this balance, and innovative therapies in this domain, we refer the readers to several reviews dealing with this topic (Ying, 2008; Teodoro et al, 2013; Xiao et al, 2018).”
BackgroundMethodInfluentialMichishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0033 · Cited by 1,364
Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
NAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255 · cited 1×
“…NAD+-enhancing molecules was successful in ameliorating the outcomes of these conditions, including neurodegenerative disorders (Liu et al, 2013; Zhou et al, 2015; Schondorf et al, 2018), metabolic diseases (Revollo et al, 2007; Yoshino et al, 2011; Canto et al, 2012; Lee et al, 2015; Katsyuba…”
BackgroundCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 1×
“Indian J Dermatol 53: 31 – 32 Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, Delphin N, Fares-Taie L, Gerber S, Xerri O et al (2012) Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy.”
BackgroundSelf-citationMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210 · cited 4×
“…case of NAM, or through the equilibrative nucleoside transporters (ENTs) SLC29A1-4 in the case of NR, both molecules are directly converted into nicotinamide mononucleotide (NMN) by the enzyme NAM phosphoribosyltransferase (NAMPT) or the NR kinases (NRKs), respectively (Mouchiroud et al, 2013a).”
BackgroundSelf-citationMills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.013 · Cited by 930 · cited 1×
“…disorders (Liu et al, 2013; Zhou et al, 2015; Schondorf et al, 2018), metabolic diseases (Revollo et al, 2007; Yoshino et al, 2011; Canto et al, 2012; Lee et al, 2015; Katsyuba et al, 2018), and age-related complications (Mouchiroud et al, 2013b; Mills et al, 2016; Zhang et al, 2016).”
BackgroundNampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911 · cited 3×
“…al, 2006; Camacho-Pereira et al, 2016), and (ii) compromised NAD+ biosynthesis, which is primarily caused by decreased NAMPT-mediated NAD+ salvage (Revollo et al, 2007; Yoshino et al, 2011; Liu et al, 2012; Ghosh et al, 2014), but also by a decrease in the activity of the mitochondrial enzyme…”
BackgroundCamacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.006 · Cited by 901
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899 · cited 3×
“…NAD(H) distribution can be explained by a combination of (i) distinct subcellular expression patterns of NAD+ biosynthetic and consuming enzymes (Houtkooper et al, 2010); (ii) organelle-specific transporters of NAD+ intermediates (Nikiforov et al, 2011; Gaudino et al, 2019); and (iii) a set of…”
BackgroundSelf-citationTherapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862 · cited 1×
“By generating the second messenger cADPr through NAD+ cleavage, cADPr synthases are able to influence intracellular calcium fluxes, cell cycle activity, insulin signaling, and the immune response (Aksoy et al, 2006; Malavasi et al, 2008;Wei et al, 2014; Ortolan et al, 2019).”
BackgroundPARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.004 · Cited by 837 · cited 1×
“Inhibition of NAD+ consumption has been proven effective in raising NAD+ levels in preclinical studies (Bai et al, 2011; Escande et al, 2013; Pirinen et al, 2014; Haffner et al, 2015).”
BackgroundSelf-citationNicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697 · cited 1×
“Admittedly, although an increase in whole blood NAD+ content was reported upon NR administration (Trammell et al, 2016; Airhart et al, 2017), supplementation with this precursor has failed to increase NAD+ in other tissues, such as muscle (Elhassan et al, 2019; Dollerup et al, 2020), even after…”
BackgroundNAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627 · cited 1×
“In fact, a large number of clinical trials have been carried out with the NAD+ precursors NA, NAM, NR, and, to a much lesser extent, NMN (Connell et al, 2019; Katsyuba et al, 2020).”
BackgroundEssuman, K., Summers, D. W., Sasaki, Y., Mao, X., DiAntonio, A., & Milbrandt, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.022 · Cited by 619
Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03421-7 · Cited by 588 · cited 1×
“…in skeletal muscle, and increases the sleeping metabolic rate to some extent (Remie et al, 2020), it has no effects on overall activity, exercise performance, motor function, or mitochondrial bioenergetics (Dollerup et al, 2018; Martens et al, 2018; Elhassan et al, 2019; Dollerup et al, 2020).”
BackgroundAge-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue
Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., & Guillemin, G. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042357 · Cited by 545 · cited 1×
“In fact, NAD+ levels are depleted in tissues from aged humans, such as skin (Massudi et al, 2012) and brain (Zhu et al, 2015).”
BackgroundNAD(+) in aging: molecular mechanisms and translational implications
Fang, E. F., Lautrup, S., Hou, Y., Demarest, T. G., Croteau, D. L., Mattson, M. P., & Bohr, V. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.001 · Cited by 501
Zhu, X.-H., Lu, M., Lee, B.-Y., Ugurbil, K., & Chen, W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417921112 · Cited by 468
Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., Cartwright, D. M., Oakey, L., Burley, C. V., Jenkinson, N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.043 · Cited by 448 · cited 3×
“…reported upon NR administration (Trammell et al, 2016; Airhart et al, 2017), supplementation with this precursor has failed to increase NAD+ in other tissues, such as muscle (Elhassan et al, 2019; Dollerup et al, 2020), even after administration of 1 g per day during 6 weeks (Remie et al, 2020).”
BackgroundExtracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice
Yoshida, M., Satoh, A., Lin, J. B., Mills, K. F., Sasaki, Y., Rensing, N., Wong, M., Apte, R. S., & Imai, S.-I. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.015 · Cited by 407 · cited 1×
“A recent study shows that eNAMPT is exclusively contained in extracellular vesicles and that the levels of this extracellular protein decline with age in mice and human plasma (Yoshida et al, 2019).”
BackgroundBiosensor reveals multiple sources for mitochondrial NAD +
Cambronne, X. A., Stewart, M. L., Kim, D., Jones-Brunette, A. M., Morgan, R. K., Farrens, D. L., Cohen, M. S., & Goodman, R. H. (2016) · Science · doi:10.1126/science.aad5168 · Cited by 407
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394 · cited 1×
“…homozygous and C/HTZ: compound heterozygous. ª 2021 The Authors EMBO Molecular Medicine 13: e13943 | 2021 7 of 15 The next step in the de novo synthesis of NAD+ is carried out by the enzyme QPRT, which converts QA, a potent excitotoxic and convulsant agent (Lugo-Huitron et al, 2013), into NaMN.”
BackgroundMandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guastella, D. B., Dawson, V. L., & Dawson, T. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5774 · Cited by 382
Gariani, K., Menzies, K. J., Ryu, D., Wegner, C. J., Wang, X., Ropelle, E. R., Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. (2016) · Hepatology · doi:10.1002/hep.28245 · Cited by 368
NAD+-Dependent Activation of Sirt1 Corrects the Phenotype in a Mouse Model of Mitochondrial Disease
Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A. A., Li, W., Leoni, V., Schon, E. A., Dantzer, F., Auwerx, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.001 · Cited by 343 · cited 1×
“…activation by increased NAD+ bioavailability has proven beneficial in a number of preclinical studies (Yoshino et al, 2011; Canto et al, 2012; Cerutti et al, 2014; Pirinen et al, 2014; Gariani et al, 2016; Jukarainen et al, 2016; Ryu et al, 2016) and has focused attention on this family of…”
Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O’Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2013) · Diabetes · doi:10.2337/db12-1139 · Cited by 332
Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells
Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213298 · Cited by 326
The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
Bai, P., & Cantó, C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.016 · Cited by 312
SLC25A51 is a mammalian mitochondrial NAD(+) transporter
Luongo, T. S., Eller, J. M., Lu, M.-J., Niere, M., Raith, F., Perry, C., Bornstein, M. R., Oliphint, P., Wang, L., McReynolds, M. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2741-7 · Cited by 308 · cited 2×
“Although the mechanism behind this differential content of NAD+ plus NADH has remained unresolved, the recent identification of SLC25A51/MCART1 as an active transporter of NAD+ from the cytosol to mitochondria may well provide an explanation (Kory et al, 2020; Luongo et al, 2020).”
BackgroundSlc12a8 is a nicotinamide mononucleotide transporter
Grozio, A., Mills, K. F., Yoshino, J., Bruzzone, S., Sociali, G., Tokizane, K., Lei, H. C., Cunningham, R., Sasaki, Y., Migaud, M. E., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0009-4 · Cited by 287 · cited 1×
“Interestingly, NMN can also act as an external NAD+ precursor via extracellular conversion to NR by the ectoenzyme 5’-nucleotidase CD73 (Garavaglia et al, 2012; Grozio et al, 2013) or through specific transport via the recently described SLC12A8 transporter (Grozio et al, 2019).”
BackgroundDollerup, O. L., Christensen, B., Svart, M., Schmidt, M. S., Sulek, K., Ringgaard, S., Stødkilde-Jørgensen, H., Møller, N., Brenner, C., Treebak, J. T., et al. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy132 · Cited by 282 · cited 2×
“…a painful flushing reaction (Benyo et al, 2005), neither NMN nor NR have been reported to cause any adverse effect (Conze et al, 2019), even after a single oral dose of 0.5 g of NMN (Irie et al, 2020) or supplementationwith NR for 3 months at doses as high as 2 g per day (Dollerup et al, 2018).”
BackgroundInfluentialNAD metabolism: Implications in aging and longevity
Yaku, K., Okabe, K., & Nakagawa, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.006 · Cited by 269
NAD + repletion improves muscle function in muscular dystrophy and counters global PARylation
Ryu, D., Zhang, H., Ropelle, E. R., Sorrentino, V., Mázala, D. A. G., Mouchiroud, L., Marshall, P. L., Campbell, M. D., Ali, A. S., Knowels, G. M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5504 · Cited by 256 · cited 1×
“…preclinical studies (Yoshino et al, 2011; Canto et al, 2012; Cerutti et al, 2014; Pirinen et al, 2014; Gariani et al, 2016; Jukarainen et al, 2016; Ryu et al, 2016) and has focused attention on this family of enzymes as potential therapeutic targets, also in humans (Jukarainen et al, 2016;…”
BackgroundPirinen, E., Cantó, C., Jo, Y. S., Morato, L., Zhang, H., Menzies, K. J., Williams, E. G., Mouchiroud, L., Moullan, N., Hagberg, C., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.002 · Cited by 254 · cited 2×
“…NAD+ bioavailability has proven beneficial in a number of preclinical studies (Yoshino et al, 2011; Canto et al, 2012; Cerutti et al, 2014; Pirinen et al, 2014; Gariani et al, 2016; Jukarainen et al, 2016; Ryu et al, 2016) and has focused attention on this family of enzymes as potential…”
BackgroundBorst, P. (2020) · IUBMB Life · doi:10.1002/iub.2367 · Cited by 252 · cited 2×
“…and (iii) a set of redox systems that interconvert NAD+ and NADH, such as the TCA cycle, complex I of the electron transport chain, various cytosolic dehydrogenases, or the malate-aspartate shuttle (also known as the Borst cycle) (Canto et al, 2015; Yang & Sauve, 2016; Borst, 2020) (Figure 2).”
BackgroundCrosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246 · cited 1×
“…more extensive coverage of NAD+-consuming enzymes, we refer the readers to several excellent reviews with more detailed information on sirtuins (Houtkooper et al, 2012; Chang & Guarente, 2014), PARPs (Schreiber et al, 2006; Canto et al, 2013; Leung, 2017), and cADPr synthases (Quarona et al, 2013).”
BackgroundNAD Deficiency, Congenital Malformations, and Niacin Supplementation
Shi, H., Enriquez, A., Rapadas, M., Martin, E. M. M. A., Wang, R., Moreau, J., Lim, C. K., Szot, J. O., Ip, E., Hughes, J. N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616361 · Cited by 246
Liu, D., Pitta, M., Jiang, H., Lee, J.-H., Zhang, G., Chen, X., Kawamoto, E. M., & Mattson, M. P. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.020 · Cited by 238 · cited 1×
“…with NAD+-enhancing molecules was successful in ameliorating the outcomes of these conditions, including neurodegenerative disorders (Liu et al, 2013; Zhou et al, 2015; Schondorf et al, 2018), metabolic diseases (Revollo et al, 2007; Yoshino et al, 2011; Canto et al, 2012; Lee et…”
BackgroundImplications of altered NAD metabolism in metabolic disorders
Okabe, K., Yaku, K., Tobe, K., & Nakagawa, T. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0527-8 · Cited by 223
Conze, D., Brenner, C., & Kruger, C. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-46120-z · Cited by 210 · cited 1×
“In contrast to NA, which induces a painful flushing reaction (Benyo et al, 2005), neither NMN nor NR have been reported to cause any adverse effect (Conze et al, 2019), even after a single oral dose of 0.5 g of NMN (Irie et al, 2020) or supplementationwith NR for 3 months at doses as high as 2 g…”
BackgroundInfluentialMCART1/SLC25A51 is required for mitochondrial NAD transport
Kory, N., uit de Bos, J., van der Rijt, S., Jankovic, N., Güra, M., Arp, N., Pena, I. A., Prakash, G., Chan, S. H., Kunchok, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe5310 · Cited by 205
NAD + metabolism: A therapeutic target for age-related metabolic disease
Mouchiroud, L., Houtkooper, R. H., & Auwerx, J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.789479 · Cited by 193 · cited 4×
“…case of NAM, or through the equilibrative nucleoside transporters (ENTs) SLC29A1-4 in the case of NR, both molecules are directly converted into nicotinamide mononucleotide (NMN) by the enzyme NAM phosphoribosyltransferase (NAMPT) or the NR kinases (NRKs), respectively (Mouchiroud et al, 2013a).”
BackgroundInfluentialSelf-citationIrie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0313 · Cited by 191
Remie, C. M., Roumans, K. H., Moonen, M. P., Connell, N. J., Havekes, B., Mevenkamp, J., Lindeboom, L., de Wit, V. H., van de Weijer, T., Aarts, S. A., et al. (2020) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa072 · Cited by 160 · cited 3×
“…(Elhassan et al, 2019), increases acetylcarnitine concentrations in skeletal muscle, and increases the sleeping metabolic rate to some extent (Remie et al, 2020), it has no effects on overall activity, exercise performance, motor function, or mitochondrial bioenergetics (Dollerup et al,…”
BackgroundSelf-citationGrozio, A., Sociali, G., Sturla, L., Caffa, I., Soncini, D., Salis, A., Raffaelli, N., De Flora, A., Nencioni, A., & Bruzzone, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470435 · Cited by 158 · cited 1×
“Interestingly, NMN can also act as an external NAD+ precursor via extracellular conversion to NR by the ectoenzyme 5’-nucleotidase CD73 (Garavaglia et al, 2012; Grozio et al, 2013) or through specific transport via the recently described SLC12A8 transporter (Grozio et al, 2019).”
BackgroundDollerup, O. L., Chubanava, S., Agerholm, M., Søndergård, S. D., Altıntaş, A., Møller, A. B., Høyer, K. F., Ringgaard, S., Stødkilde‐Jørgensen, H., Lavery, G. G., et al. (2020) · The Journal of Physiology · doi:10.1113/jp278752 · Cited by 145
van de Weijer, T., Phielix, E., Bilet, L., Williams, E. G., Ropelle, E. R., Bierwagen, A., Livingstone, R., Nowotny, P., Sparks, L. M., Paglialunga, S., et al. (2015) · Diabetes · doi:10.2337/db14-0667 · Cited by 139 · cited 1×
“Moreover, these molecules have been described to have potential benefits for chronic kidney disease (Restrepo Valencia & Cruz, 2008; Jin Kang et al, 2013) and the physiological functioning of mitochondria in muscle of subjects with type 2 diabetes (van de Weijer et al, 2015).”
BackgroundHaffner, C. D., Becherer, J. D., Boros, E. E., Cadilla, R., Carpenter, T., Cowan, D., Deaton, D. N., Guo, Y., Harrington, W., Henke, B. R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm502009h · Cited by 137 · cited 1×
“Inhibition of NAD+ consumption has been proven effective in raising NAD+ levels in preclinical studies (Bai et al, 2011; Escande et al, 2013; Pirinen et al, 2014; Haffner et al, 2015).”
Backgroundde Guia, R. M., Agerholm, M., Nielsen, T. S., Consitt, L. A., Søgaard, D., Helge, J. W., Larsen, S., Brandauer, J., Houmard, J. A., & Treebak, J. T. (2019) · Physiological Reports · doi:10.14814/phy2.14139 · Cited by 99
Garavaglia, S., Bruzzone, S., Cassani, C., Canella, L., Allegrone, G., Sturla, L., Mannino, E., Millo, E., De Flora, A., & Rizzi, M. (2012) · Biochemical Journal · doi:10.1042/bj20111263 · Cited by 94 · cited 4×
“In this new metabolic route, NMNH is cleaved by CD73 to NRH, which is then taken up by the same transporters (ENTs) as NR. Inside the cell, NRH is phosphorylated back to NMNH by adenosine kinase (AK), after which NMNH is finally converted into NADH by the NMNATs, which is then interconverted into NAD+ by the large var…”
BackgroundInfluentialRoles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca2+signaling pathway
Wei, W. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i1.58 · Cited by 89
Watson, A., Nong, Z., Yin, H., O’Neil, C., Fox, S., Balint, B., Guo, L., Leo, O., Chu, M. W. A., Gros, R., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.310022 · Cited by 72 · cited 1×
“In fact, only a few reports have shown impaired NAMPT activity or PARP1 overactivation in elderly or obese subjects (Barth et al, 2010; Dahl et al, 2010; Gaddipati et al, 2010; Jukarainen et al, 2016; Zhou et al, 2016), which has also been linked to thoracic aortic aneurysms (Watson et al, 2017).”
BackgroundLeung, A. K. L. (2017) · Current Biology · doi:10.1016/j.cub.2017.09.054 · Cited by 44 · cited 3×
“Similar to sirtuins, the DNA damage-activated poly(ADP-ribose) polymerases (PARPs) consume NAD+ during transfer of ADP-ribosyl moieties to other proteins (Leung, 2017).”
Background
Cited by
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease
Nguyen, T. T., Wei, S., Nguyen, T. H., Jo, Y., Zhang, Y., Park, W., Gariani, K., Oh, C.-M., Kim, H. H., Ha, K.-T., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01046-5 · Cited by 325
Self-citationHuang, Y., Meng, K., Liu, G., Chen, Z., Han, Y., Yang, P., Zhang, R., & Cai, H. (2025) · Biology · doi:10.3390/biology14091167 · Cited by 7
Metadata
- Authors
- Zapata‐Pérez, R., Wanders, R. J. A., van Karnebeek, C. D. M., & Houtkooper, R. H.
- Venue
- EMBO Molecular Medicine
- Published
- 2021-05-27
- Volume
- 13
- Issue
- 7
- Pages
- e13943-e13943
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3165186859
- Cited by
- 238
- References
- 59
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.